指南与共识肝病

AGA临床实践更新:肝硬化腹水、容量负荷过重及低钠血症的管理

AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review.
指南 / 共识 · Gastroenterology · 2025-10-20

美国胃肠病学会(AGA)发布专家综述,总结肝硬化腹水、肝性胸水、容量负荷过重及低钠血症管理的循证证据并给出13条最佳实践建议。内容涵盖限钠利尿、诊断性穿刺、白蛋白输注、TIPS转诊、低钠血症门诊与住院处理及难治性病例的多学科策略。

要点

  • 肝硬化腹水患者应限钠利尿,以最低有效剂量起始,根据症状、体重、尿量及电解质调整。
  • 新发腹水或腹水/脑病相关住院应尽快诊断性穿刺,检测SAAG、细胞计数、革兰染色及培养。
  • 难治性腹水/肝性胸水应评估肝移植,无论MELD评分;大量放腹水>5L按每升6-8g白蛋白补充。

核心结论

  • 肝硬化腹水、肝性胸水、容量负荷过重及低钠血症的管理应基于限钠利尿、及时诊断性穿刺及个体化白蛋白/血管活性药物等多模式策略。

研究设计与样本

  • AGA研究所临床实践更新(CPU)专家综述,由AGA理事会及临床实践更新委员会委托并批准,经内部及外部同行评议,基于文献综述与专家意见形成最佳实践建议(BPA),未进行正式系统评价,故无证据质量或推荐强度分级。

主要发现

  • 肝硬化腹水、肝性胸水或容量负荷过重患者应接受限钠饮食及最低有效剂量利尿剂,剂量调整依据症状、体重、尿量及电解质/肾功能监测。
  • 新发腹水或因腹水/脑病相关症状住院者应尽快诊断性穿刺,检测血清腹水白蛋白梯度(SAAG)、细胞计数、革兰染色及培养。
  • 肝性胸水伴呼吸困难和/或低氧血症者应行治疗性胸腔穿刺以缓解症状并促进肺复张。
  • 难治性腹水和/或肝性胸水患者无论MELD评分均应考虑肝移植评估。
  • 放腹水量>5L时,每放1L腹水应静脉给予20%-25%白蛋白6-8g;低血压、肾功能不全或电解质异常者较小放液量也应考虑白蛋白。

关键数值与推荐

  • 限钠饮食及利尿剂应以最低有效剂量起始,剂量升级依据症状、体重、尿量及电解质/肾功能监测。
  • 诊断性穿刺检测项目包括SAAG、细胞计数、革兰染色及培养。
  • 放腹水>5L时,每升腹水给予20%-25%白蛋白6-8g;低血压、肾功能不全或电解质异常者较小量放液也应考虑白蛋白。
  • 无症状高容量性低钠血症门诊管理:限钠限水(每日液体摄入目标1-1.5L),调整利尿剂及泻药,监测电解质。
  • 容量负荷过重住院管理:静脉袢利尿剂(呋塞米或布美他尼)可每日2-3次弹丸式注射或持续输注,每2-3天谨慎升级并监测容量状态、肾功能、每日体重及症状。

临床怎么用

  • 对肝硬化腹水或容量负荷过重患者,应提供饮食教育并转诊营养师,同时识别并处理肝失代偿诱因。
  • 难治性腹水/肝性胸水应转诊评估经颈静脉肝内门体分流术(TIPS),并考虑肝移植评估。
  • 低钠血症诊断应评估饮食及药物史(利尿剂、肠道方案)、电解质及肾功能、消化道出血、感染(含诊断性穿刺)及继发原因(甲状腺或肾上腺功能障碍)。
  • 严重或有症状的高容量性低钠血症住院管理包括限钠限水、调整或停用利尿剂及泻药,并根据容量评估加用静脉白蛋白或口服血管收缩治疗。
  • 难治性全身水肿可与肾内科协作,考虑 contraction alkalosis 时加用乙酰唑胺、换用噻嗪类利尿剂(如美托拉宗)或超滤。

局限性

  • 本专家综述未进行正式系统评价,最佳实践建议基于文献综述与专家意见,不携带正式证据质量或推荐强度分级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) is to summarize the available evidence and offer expert Best Practice Advice (BPA) on the management of ascites, hepatic hydrothorax, volume overload, and hyponatremia in patients with cirrhosis. METHODS: This expert review was commissioned and approved by the AGA Institute Governing Board and Clinical Practice Updates Committee (CPUC) to provide timely guidance on a topic of high clinical importance to the AGA membership. This CPU expert review underwent internal peer review by the CPUC and external peer review through the standard procedures of Gastroenterology. These BPA statements were developed based on review of the published literature and expert opinion and approved by the AGA Institute Governing Board. Because formal systematic reviews were not performed, these BPA statements do not carry formal ratings of the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: Patients with cirrhosis with ascites, hepatic hydrothorax, or volume overload should be managed with dietary sodium restriction and diuretics at the lowest effective dose, with dose escalation guided by symptoms, weight, urine output, and electrolyte/renal monitoring. Education and referral to a dietitian should be provided for dietary management. Triggers of liver decompensation should be identified and addressed. BEST PRACTICE ADVICE 2: Patients with cirrhosis with new-onset ascites, or those admitted to the hospital for symptoms related to ascites or encephalopathy should receive diagnostic paracentesis as soon as possible. Testing should include serum ascites albumin gradient and cell count, Gram stain, and culture. BEST PRACTICE ADVICE 3: Patients with hepatic hydrothorax with dyspnea and/or hypoxemia should undergo a therapeutic thoracentesis for both symptom relief and expansion of the underlying lung. BEST PRACTICE ADVICE 4: All patients with refractory ascites and/or hepatic hydrothorax should be considered for liver transplantation evaluation, regardless of their Model for End-Stage Liver Disease score. BEST PRACTICE ADVICE 5: Refractory ascites and/or hydrothorax should be managed with therapeutic paracentesis and/or thoracentesis, respectively, with the frequency guided by recurrence. BEST PRACTICE ADVICE 6: When the volume of ascites removed is >5 L, 20%-25% intravenous albumin 6-8 g per every total liter removed should be administered. For patients with hypotension, renal insufficiency, or electrolyte abnormalities, albumin should also be considered for removal of smaller volumes. BEST PRACTICE ADVICE 7: Well-selected patients with refractory ascites, hepatic hydrothorax, volume overload, or hyponatremia should be referred for to transjugular intrahepatic portosystemic shunt. BEST PRACTICE ADVICE 8: Diagnostic workup for the etiology of hyponatremia in cirrhosis should include dietary and medication history (diuretics, bowel regimen); review of electrolyte and kidney function; gastrointestinal bleeding assessment; infectious workup, including diagnostic paracentesis, and evaluation of secondary causes (thyroid or adrenal dysfunction). BEST PRACTICE ADVICE 9: Outpatient management of asymptomatic hypervolemic hyponatremia in liver cirrhosis entails both sodium and water restriction (aiming for 1-1.5 L of daily fluid intake), modification of diuretics and laxatives, and monitoring of electrolytes. BEST PRACTICE ADVICE 10: Inpatient management of severe or symptomatic hypervolemic hyponatremia in liver cirrhosis includes both sodium and water restriction; modification or discontinuation of diuretics and laxatives; and additional measures, such as intravenous albumin based on volume assessment or oral vasoconstriction therapy. BEST PRACTICE ADVICE 11: Recurrent or refractory hyponatremia management should involve a multidisciplinary approach (including the liver transplantation team when appropriate) and can consider several therapeutic options, including intravenous vasoconstrictor therapy, infusion of hypertonic saline, use of vasopressin receptor antagonist (vaptans), or use of renal replacement therapy. BEST PRACTICE ADVICE 12: Inpatient management of volume overload includes escalation or trial of intravenous loop diuretics (furosemide or bumetanide) in bolus (2-3 times per day) or continuous fashion. Cautious escalation can be done every 2-3 days with monitoring of volume status, kidney function, daily weights, and symptoms. BEST PRACTICE ADVICE 13: Advanced strategies in refractory anasarca should be coordinated with nephrology for consideration of diuretics in the setting of contraction alkalosis (eg, addition of acetazolamide), second agent with alternate mechanism of actions (eg, thiazide diuretics, such as metolazone), or need for ultrafiltration.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Orman ES, Fortune BE, John BV, et al. AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review. Gastroenterology. 2025. PMID: 41114681. doi:10.1053/j.gastro.2025.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。